Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Summary

Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).

Timeline

Start

2023-11-12

Primary completion

2026-05-13

Completion

2028-05-13

Drugs

Indications